Not applicableStudy completedNCT03718117What this trial is testingDescriptive Observational Study ALK-2016-CPHGWho this might be right forNSCLCCrizotinibALK Gene Rearrangement or ROS1 Gene Rearrangement Pfizer 73
Not applicableUnknownNCT04921553What this trial is testingReal Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)Who this might be right forCancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more Centre Leon Berard 500
Testing effectiveness (Phase 2)UnknownNCT01964157What this trial is testingAn Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementWho this might be right forNon-small Cell Lung Cancer (NSCLC) Yonsei University 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772What this trial is testingPhase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Who this might be right forNon-Small Cell Lung Cancer AstraZeneca 247
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267What this trial is testingBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Who this might be right forBreast CancerCholangiocarcinomaColorectal Cancer+13 more Hoffmann-La Roche 534
Early research (Phase 1)WithdrawnNCT05828303What this trial is testingEvaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid TumorsWho this might be right forAdvanced Solid TumorMetastatic Solid Tumor Turning Point Therapeutics, Inc.
Testing effectiveness (Phase 2)UnknownNCT04292119What this trial is testingLorlatinib Combinations in Lung CancerWho this might be right forLung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 Rearrangement+4 more Massachusetts General Hospital 96
Testing effectiveness (Phase 2)Looking for participantsNCT03093116What this trial is testingRepotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsWho this might be right forLocally Advanced Solid TumorsMetastatic Solid Tumors Turning Point Therapeutics, Inc. 500
Early research (Phase 1)Study completedNCT00585195What this trial is testingOral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced CancerWho this might be right forNon-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more Pfizer 596
Testing effectiveness (Phase 2)Looking for participantsNCT05118789What this trial is testingZidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)Who this might be right forLocally Advanced Solid TumorMetastatic Solid Tumor Nuvalent Inc. 359
Testing effectiveness (Phase 2)Looking for participantsNCT06552234What this trial is testingPhase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLCWho this might be right forNSCLC Stage IVNSCLC, Stage III Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer 30
Testing effectiveness (Phase 2)UnknownNCT04989322What this trial is testingPembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCWho this might be right forNsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more Dr Joanne CHIU 46
Testing effectiveness (Phase 2)UnknownNCT03399487What this trial is testingLDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementWho this might be right forNon-small Cell Lung Cancer Harboring ROS1 Rearrangement Yonsei University 46
Early research (Phase 1)Ended earlyNCT04005144What this trial is testingBrigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung CancerWho this might be right forALK Gene RearrangementLung Non-Small Cell CarcinomaProgressive Disease+6 more University of California, San Francisco 3
Not applicableNot Yet RecruitingNCT06694129What this trial is testingReal-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLCWho this might be right forNon-Small Cell Lung CancerROS1 Gene RearrangementResistance+1 more National Cancer Center, China 40
Large-scale testing (Phase 3)Looking for participantsNCT04603807What this trial is testingCompare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesWho this might be right forCarcinoma, Non-Small-Cell Lung Hoffmann-La Roche 220
Not applicableStudy completedNCT03727477What this trial is testingEfficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving LorlatinibWho this might be right forNon-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive Intergroupe Francophone de Cancerologie Thoracique 291
Early research (Phase 1)Study completedNCT05055232What this trial is testingA Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung CancerWho this might be right forROS1 Rearrangement Non-small Cell Lung CancerALK Rearrangement Non-small Cell Lung Cancer Xuanzhu Biopharmaceutical Co., Ltd. 114
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401What this trial is testingStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsWho this might be right forSolid TumorsCNS Tumors Hoffmann-La Roche 69
Testing effectiveness (Phase 2)UnknownNCT03608007What this trial is testingX-396 Capsule in Advanced NSCLC Patients With ROS1 Gene RearrangementWho this might be right forLung CancerROS1 Gene Rearrangement Betta Pharmaceuticals Co., Ltd. 69